COVID-19

SARS-CoV-2 Serology and Self-Reported Infection Among Adults — National Health and Nutrition Examination Survey, United States, August 2021–May 2022 | Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes | Serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individuals
| Sensitivity of anti-SARS-CoV-2 nucleocapsid protein antibody for breakthrough infections during the epidemic of the Omicron variants | Mpox (formerly monkeypox) in women: epidemiological features and clinical characteristics of mpox cases in Spain, April to November 2022 | Triage of patients with Ebola virus disease

Is the risk of still and preterm birth affected by the timing of symptomatic SARS-CoV-2 infection during pregnancy? | Effectiveness of Influenza Vaccination of Pregnant Women for Prevention of Maternal and Early Infant Influenza-Associated Hospitalizations in South Africa | A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes | Single and 2-dose vaccinations with modified vaccinia Ankara-Bavarian Nordic® induce durable B cell memory responses comparable to replicating smallpox vaccines | Cross-neutralization of Omicron subvariants after heterologous NVX-CoV2373 boosters: Comparison between prior SARS-CoV-2-infected and infection-naive individuals

Low Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission by Fomites: A Clinical Observational Study in Highly Infectious Coronavirus Disease 2019 | Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection | Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution | Can SARS-CoV-2 trigger new onset of autoimmune disease in adults? A case-based review | Protection against Omicron from Vaccination and Previous Infection in a Prison System | Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19

Severe Monkeypox in Hospitalized Patients — United States, August 10–October 10, 2022 | Reinfections with Different SARS-CoV-2 Omicron Subvariants, France (CDC) | In adults with COVID-19, melatonin was assessed for effects on inflammatory markers, clinical signs and symptoms, and mortality | Influenza Incidence and Vaccine Effectiveness During the Southern Hemisphere Influenza Season — Chile, 2022 | Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants | Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses

Progress Toward Poliomyelitis Eradication — Pakistan, January 2021–July 2022 | Polio by the Numbers—A Global Perspective | Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector RSV Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV Seropositive Children 12–24 Months | Receipt of First and Second Doses of JYNNEOS Vaccine for Prevention of Monkeypox — United States, May 22–October 10, 2022 | Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages

A healthcare-associated infection with Monkeypox virus of a healthcare worker during the 2022 outbreak | Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomized ascending dose phase I trial | Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment | Early outpatient treatment with remdesivir in patients at high risk for severe COVID-19: a prospective cohort study

Possible Occupational Infection of Healthcare Workers with Monkeypox Virus, Brazil | Protection of SARS-CoV-2 natural infection against reinfection with the BA.4 or BA.5 Omicron subvariants | Rates of Monkeypox Cases by Vaccination Status | Paxlovid Significantly Reduces COVID-19 Hospitalizations and Deaths | Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19